Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for New Jersey Only)
Policy governing coverage and medical necessity of occipital nerve injections (greater occipital nerve blocks) and occipital nerve ablation/neurolytic procedures for members in New Jersey.
Policy Summary
PayerUnitedHealthcare
PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for New Jersey Only)
Key ActionVerify member benefits and obtain prior authorization when required, documenting prior conservative therapy and diagnostic block or trial response.
Added definitions for the Migraine Disability Assessment Test (MIDAS) and the Migraine-Specific Quality of Life Questionnaire (MSQ).
Updated Supporting Information, Clinical Evidence, and References sections to reflect the most current information.
NJ onlyGeographic applicability
64405Referenced procedure code for GONB
2022–2024Evidence base timeframe
50%Common responder threshold
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
2New definitions added
27%High complication/removal rate (max reported)
Coverage Positions and Evidence Summaries
inv-01: Covered when related to malignancy — coverage rationale summarized
Covered when ALL of the following are met:
Covered for malignancy-related head/neck pain: Injection of local anesthetics and/or steroids as greater occipital nerve blocks (GONBs) and occipital nerve ablation (destruction by neurolytic agent) are proven and medically necessary for treating pain due to malignancy involving the head and neck.
Document lists these interventions as proven and medically necessary for malignancy-related pain.
inv-02: Not medically necessary / unproven for occipital neuralgia or headaches — listing of exclusions and rationale
Not medically necessary / unproven for occipital neuralgia or headaches (including migraine and cervicogenic headaches) due to insufficient evidence:
Unproven / Not Medically Necessary Procedures: Injection of local anesthetics and/or steroids used as GONBs (for diagnosis/treatment of occipital neuralgia or headaches), neurostimulation/electrical stimulation, occipital neurectomy, partial posterior intradural C1-C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1-C3 dorsal roots, surgical decompression of second cervical nerve root and ganglion, and surgical decompression of the greater occipital nerve are considered unproven and not medically necessary due to insufficient evidence of efficacy.
Policy text explicitly classifies these interventions as unproven/not medically necessary for ON/headache indications; multiple systematic reviews and RCTs cited show limited, short-term, or low-quality evidence.
inv-03: Evidence summary for GONB — coverage-relevant evidence findings
Summary of coverage-relevant evidence findings (not prescriptive criteria):
GONB short-term efficacy: Randomized trials and meta-analyses report that GONB with local anesthetic can reduce headache intensity and days in the short term (hours to months) across migraine, cervicogenic headache, cluster headache, and post-dural puncture headache; effect sizes and duration vary and evidence quality is generally low to moderate.
Meta-analyses report pooled reductions (e.g., -3.6 headache days/month in one analysis) and short-term benefits up to 24–48 hours for PDPH; systematic reviews and Hayes assessments note low-quality evidence and need for larger RCTs.
inv-04: Evidence summary for surgical treatments — surgical interventions evidence
Surgical interventions evidence summary:
Surgical procedures for ON/cervicogenic headache: Available evidence for surgical interventions (neurectomy, neurolysis/neuroplasty, trigger-site surgery, nerve decompression, dorsal root section, rhizotomy) is limited and primarily observational; some meta-analyses report clinically meaningful reductions in frequency/severity for selected surgical cohorts, but long-term efficacy and high‑quality RCT data are lacking.
Trigger-site surgery pooled analyses report elimination of migraine in ~38% at 6–12 months, but selection bias and lack of RCTs limit conclusions; reviews call for randomized trials.
inv-05: Coverage considerations and selection criteria — evidence and coverage considerations
Evidence and coverage considerations summarized from the literature:
Require prior conservative therapy and diagnostic block response: Patients considered for surgical or ablative interventions should have medically refractory occipital neuralgia or headache after adequate conservative therapy and should demonstrate a positive response to diagnostic occipital (GON) or C2 DRG blocks when applicable.clinical response to diagnostic block (e.g., >=50% pain reduction)
Systematic reviews and observational series report better outcomes in patients with prior positive diagnostic block responses; small studies commonly used >=50% as response threshold.
Modality-specific evidence notes: Pulsed radiofrequency (PRF) has small RCTs/series suggesting benefit and favorable safety compared with thermal RFA; thermal (nonpulsed) RFA evidence is limited with few RCTs and concerns about neurodestructive complications.study-dependent
Reviews and best-practices note PRF preferred over thermal RFA pending higher-quality trials.
inv-06: Implanted neurostimulation — selection and response evidence and considerations
Evidence and selection considerations for implanted neurostimulation (ONS/SCS/PNS):
Patient selection and trial requirement: Implantable neurostimulation studies typically required prior failure of conservative therapies and a positive temporary stimulation trial before permanent implantation.trial response often >=30% or >=50% depending on study
Hayes and cohort studies frequently used a >=50% trial response to select implant candidates; some series used >=30% for trial response (Joswig et al.).
Outcomes and risks: Reported response rates for ONS are variable across headache types; long-term responder rates and complication/revision rates are nontrivial, with infection and hardware issues reported in several series.examples: long-term >=50% pain reduction ~57.1% in one cohort; device removal/infection rates up to ~27% in some reports
Systematic reviews and device series highlight heterogeneous benefits and potential need for additional surgeries.
inv-07: PRF/PRFN — evidence and durability for pulsed radiofrequency
Pulsed radiofrequency (PRF/PRFN) for peripheral nerves (GON, supraorbital, SPG):
PRF evidence and durability: Observational and small prospective studies report short- to mid-term pain reduction after PRF/PRFN for occipital neuralgia, supraorbital neuralgia, and chronic migraine; durability is variable with good early response and decline in some series over 1–2 years.effectiveness variable (e.g., supraorbital neuralgia effectiveness: 77% at 1 month → 50% at 2 years)
Narrative reviews and small studies emphasize need for larger RCTs to define optimal targets and long-term benefit.
REN RCT findings: A multicenter randomized trial of remote electrical neuromodulation (REN) demonstrated statistically significant reductions in monthly migraine days and moderate/severe headache days versus placebo, with no serious device-related adverse events.therapeutic gain ~2.7 mean days/month; 51.6% achieved 50% reduction in moderate/severe headache days
Trial limitations include inclusion of participants on a single preventive agent and migraine-day definition concerns.
tDCS and combined noninvasive stimulation: Small RCTs of tDCS and combined external occipital/trigeminal stimulation for acute or preventive migraine show potential benefit versus sham, but overall evidence is limited and further high-quality RCTs are needed.variable by trial
Systematic reviews and technology assessments characterize evidence as low-to-moderate quality.
SCS evidence: Observational and small prospective studies report possible reductions in migraine days and intensity with cervical or high-frequency SCS (examples include mean MMD reduction of 9.3 days at 52 weeks in a 20‑patient 10 kHz study), but evidence quality is very low and sample sizes are small.small sample sizes; no large RCTs
Systematic reviews conclude promising but low‑quality evidence and call for well‑powered randomized trials.
inv-10: Interventional neuromodulation coverage criteria (document-derived) — 'Covered when ALL of the following are met' guidance
Covered when ALL of the following are met (where applicable based on intervention):
Staged selection and documentation: Patient has undergone appropriate conservative and diagnostic interventions (e.g., trials of guideline-directed medical therapy and diagnostic occipital or C2 DRG nerve block) with documented positive response to the diagnostic intervention or trial stimulation.>=50% improvement commonly used
Policy and evidence summaries and HTA reports commonly required documentation of prior conservative therapy failure and a positive diagnostic or trial response (often >=50%) before considering definitive invasive therapy.
Imaging and differential diagnosis: Other possible etiologies have been evaluated and ruled out with MRI and/or CT when indicated prior to irreversible neurotomy or implantation.
Best-practices recommend imaging to exclude alternative causes before RFN despite imaging not being diagnostic for occipital neuralgia.
Risk/benefit documentation:
inv-11: Guideline-based coverage considerations — guidance from NICE, VA/DoD, Congress of Neurological Surgeons
Guidance from cited guideline sources and implications for coverage decisions:
ONS recommendation (Congress of Neurological Surgeons): Congress of Neurological Surgeons: ONS may be used as a treatment option for medically refractory occipital neuralgia (Level III).medically refractory
Level III recommendation reflects limited-quality evidence and small studies; supports consideration in selected refractory cases.
NICE and VA/DoD guidance: NICE: several neuromodulation and transcutaneous stimulation procedures should be used only with special arrangements for governance, consent, audit, or in research; VA/DoD: insufficient evidence to recommend for or against many neuromodulation modalities (including GONB for preventing chronic migraine).use in tertiary centers/research or with special arrangements
Guidelines emphasize need for careful patient selection, documentation, and further research.
This policy enumerates a range of surgical and procedural interventions and specifies their coverage stance. Injection of local anesthetic and/or steroid as greater occipital nerve blocks (GONBs) and occipital nerve ablation (destruction by neurolytic agent) are identified as proven and medically necessary when treating pain due to malignancy of the head and neck. Conversely, the policy lists other procedures—including GONBs (for non-malignant ON/headache indications), neurostimulation/electrical stimulation, occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed), rhizotomy of C1–C3 dorsal roots, and surgical decompression procedures—as unproven and not medically necessary for diagnosing or treating occipital neuralgia or headaches because of insufficient evidence of efficacy.
A focused evidence assessment found insufficient published peer‑reviewed clinical trial evidence to support neuroplasty for occipital neuralgia. The Hayes review identified no randomized controlled trials and only a small number of observational reports, and therefore concluded that available literature does not permit firm conclusions about safety or effectiveness of neuroplasty for ON.
Available data for occipital neurectomy and nerve decompression procedures are limited and primarily observational. The policy states that evidence is insufficient to conclude these surgeries are effective for headaches, and that long‑term efficacy has not been established in well‑designed clinical trials.
Certain procedures are supported only by very low‑quality, heterogeneous, or sparse evidence. For example, reviews of occipital nerve stimulation (ONS) for chronic cluster headache report small study numbers, inconsistent outcomes, and very low quality of evidence, such that effectiveness for this indication remains uncertain.
For some applications of occipital nerve stimulation (ONS) and related implanted neuromodulation, the literature is limited to small observational series and a few heterogeneous trials; overall the evidence is described as insufficient or very low quality and randomized, controlled data are lacking to establish consistent benefit and long‑term safety.
The policy notes that use of botulinum toxin A (BTX‑A) for cervicogenic headache or occipital neuralgia is an off‑label application: BTX‑A is not FDA‑approved specifically for these diagnoses, and this use should be documented as off‑label when considered.
Injection of local anesthetics, often with or without corticosteroid, as a greater occipital nerve block (GONB) is discussed both as a diagnostic tool and as a short‑term therapeutic intervention. Randomized trials and meta‑analyses report reductions in pain intensity and headache days for short follow‑up intervals, but effect sizes and duration vary; the policy therefore treats GONBs as useful diagnostically and potentially therapeutic but unproven for routine coverage in non‑malignancy indications.
Surgical procedures for occipital neuralgia and related disorders that lack randomized controlled trials or adequate peer‑reviewed evidence—including neuroplasty and other decompression/neurectomy techniques—are called out as having insufficient high‑quality evidence and may be considered not medically necessary in the absence of robust supporting data or strong case justification.
For nonpulsed (thermal) percutaneous radiofrequency ablation (RFA), the policy references technology assessments that found an inadequate volume of published peer‑reviewed literature and identified no randomized controlled trials in some reviews, indicating evidence is insufficient to support routine use for occipital neuralgia.
Many peripheral and implanted neuromodulation interventions (PNS/ONS and some spinal cord stimulation approaches) are supported predominantly by small, uncontrolled series or low‑quality trials. The policy summarizes these modalities as having inconsistent evidence and limited high‑quality randomized trial data, such that routine coverage is not established for many indications outside carefully selected, refractory patients.
Guideline groups and systematic reviews report insufficient evidence for several neuromodulation modalities—particularly noninvasive techniques such as some forms of tDCS, rTMS, external trigeminal or vagus nerve stimulation—and recommend that these approaches either be used only in research settings or that further high‑quality trials are required before broader adoption.
The VA/DoD 2023 guideline states there is insufficient evidence to recommend for or against greater occipital nerve block (GONB) for preventing chronic migraine, reflecting uncertain preventive benefit in guideline assessments.
Prerequisites and Step-wise Care Expectations
inv-78: Document trial of standard medical therapies and noninvasive measures prior to surgical interventions
Document trial of standard medical therapies and noninvasive measures: Documented trial of standard medical therapies (e.g., guideline-directed pharmacologic prophylaxis and acute therapies) and noninvasive measures should be completed prior to consideration of surgical interventions.
Hayes reports and systematic reviews emphasize conservative-first expectation and limited evidence for interventional procedures without prior medical therapy trials.
inv-79: Trial of conservative therapy and positive diagnostic block response before invasive procedures is expected
Trial of conservative therapy and positive diagnostic block response expected: A trial of conservative therapy with documented inadequate response and a positive diagnostic occipital or C2 DRG block response is expected before invasive procedures such as RFN, surgical decompression, or neurectomy.positive response commonly defined as >=50% pain reduction
Prior Authorization, Documentation, and Operational Guidance
Prior Authorization
Provider Action — Prior Authorization, Documentation, and Billing Guidance
The following provider-action items summarize prior authorization, documentation, coding, and operational requirements applicable to services discussed in this policy. Verify member benefit plan terms (federal, state, or contractual) before rendering services; plan terms govern.
Prior authorization may be required — verify member benefit plan and use applicable utilization review tool (e.g., InterQual) before scheduling invasive procedures or device implantation.
Document indication, prior conservative therapies tried and failed, diagnostic criteria, exam findings, imaging results (if performed), and objective outcome measures (eg, MIDAS, MSQ) when requesting authorization.
For staged/step approaches to neurostimulation or occipital procedures, document positive response to diagnostic blocks or temporary trial stimulation (commonly ≥50% pain reduction) prior to permanent implantation.
For ablation, RFA, or surgical interventions, document prior conservative therapy failure and favorable diagnostic block response when applicable.
When procedures are performed for pain due to malignancy, note that certain interventions (eg, GONB, neurolytic ablation) may be considered medically necessary — include oncologic indication in documentation.
Procedures or devices considered unproven or not medically necessary in this policy (eg, occipital neurectomy, partial posterior intradural C1-C3 rhizotomy, certain neuroplasties, some neurostimulation uses) carry a higher denial risk; include thorough supporting documentation if requested.
Procedure, Diagnosis, and Device Codes
Referenced CPT and related neurostimulation codesCPT
Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570
Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64575
Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64590
Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64596
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
1–10 of 12
1/2
Additional CPT, HCPCS, and ICD-10 codes referencedmixed
64633
Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint.
64634
Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure).
64722
Decompression; unspecified nerve(s) (specify).
64744
Transection or avulsion of; greater occipital nerve.
64771
Transection or avulsion of other cranial nerve, extradural.
64999
Unlisted procedure, nervous system.
A4540
Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm.
L8679
Implantable neurostimulator, pulse generator, any type.
L8680
Implantable neurostimulator electrode, each.
L8685
Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
1–10 of 12
1/2
Referenced procedures (codes not listed here)mixed
Not specified in this excerpt
CPT/HCPCS procedure codes for occipital nerve blocks, radiofrequency ablation, surgical decompression, neurectomy and nerve stimulation are referenced conceptually but exact numeric codes are not listed in these chunks.
Coding references in this chunk setmixed
N/A
No explicit CPT/HCPCS/ICD-10 codes provided in this document section; procedural and device coding discussed conceptually in the cited sections.
Referenced interventions/technologies (no explicit codes listed in this excerpt)mixed
No codes listed
Device product codes (FDA 510(k) listings)mixed
GXD
FDA product code for radiofrequency lesion generators.
GXI
FDA product code for radiofrequency lesion probes.
GZF
FDA product code related to electrical stimulation devices.
GZB
FDA product code related to electrical stimulation devices.
PCC
FDA product code related to electrical stimulation devices.
Trial response thresholds reported in studies — commonly ≥30% or ≥50% pain reduction used to define response
Common trial thresholds reported in studiesStudies commonly defined a positive trial response as either ≥30% or ≥50% reduction in pain, depending on the series.
Study-specific example (ONS)Joswig et al. selected trial responders using a ≥30% improvement threshold during a ~22-day trial period.
Study-reported responder metrics (ONS reviews)Hayes and other reviews commonly report outcomes using ≥50% reduction as a responder threshold for permanent implantation selection.
Responder threshold — commonly ≥50% reduction in headache frequency/intensity
Common responder threshold
Frequency, Re-treatment, and Interval Guidance
Codes for neurolytic procedures and imaging-guided injections referenced — implies imaging guidance; no explicit numeric frequency limits here
Imaging guidance implied by CPT descriptorsCodes such as 64633/64634 (destruction by neurolytic agent with imaging guidance) and others referenced imply use of fluoroscopy or CT image guidance for neurolytic procedures.
Referenced neurostimulation and implant codesMultiple CPT/HCPCS codes for neurostimulator implantation and components are listed (e.g., 64553, 64555, L8679, L8680), with device components regulated via FDA 510(k) listings.
RFA device regulatory noteDevices used for RFA are regulated via FDA 510(k) product codes (e.g., GXD, GXI) though the procedure itself is not FDA-regulated.
Electrical stimulation device product codesElectrical stimulation devices referenced have FDA 510(k) product codes (e.g., GZF, GZB, PCC), indicating regulated device components for stimulation procedures.
GONB practices reported in literature — repeated blocks weekly up to 3-4 weeks then monthly maintenance in some series
Image Guidance and Diagnostic Imaging
Billing Rule
CPT codes implying imaging guidance
CPT codes 64633 and 64634 describe destruction by neurolytic agent with imaging guidance and imply use of fluoroscopy or CT for certain neurolytic procedures; use of imaging guidance should be documented when these codes are billed.
64633/64634 descriptions explicitly reference imaging guidance (fluoroscopy or CT).
Document the imaging modality used when submitting claims for neurolytic procedures.
Billing Rule
GONB — ultrasound commonly used
Ultrasound guidance is commonly used for greater occipital nerve blocks in the literature; when US guidance is used, document the modality and target location in the procedural note.
Several RCTs and trials described US-guided proximal or distal GONB techniques.
Key Terms and Instruments
Cervicogenic Headache — definition and source (IHS/American)
DefinitionCervicogenic headache: Referred pain perceived in the head from a source in the neck caused by disorder of the cervical spine and its components (American Migraine Foundation).
Clinical cause examplesMay be due to bony, disc, and/or soft tissue elements of the cervical spine producing referred head pain.
Policy instructionRefer to federal, state, or contractual definitions that supersede these definitions when applicable.
Neurectomy — partial or total excision or resection of a nerve (Taber's)
DefinitionNeurectomy: Partial or total excision or resection of a nerve (Taber's Medical Dictionary).
Typical contextDescribed among surgical options for occipital neuralgia and nerve decompression procedures in the literature.
Procedures Considered Not Medically Necessary / Experimental
The items grouped here are placeholders representing procedures and technologies identified in the policy as not supported for routine coverage due to limited or low‑quality evidence. See the Not Medically Necessary and Exclusions sections for the specific modalities referenced throughout this policy.
This duplicate placeholder preserves the inventory grouping for procedures designated as not covered or investigational in the policy; consult the main exclusions list for detailed items.
This placeholder maintains inventory structure for additional items listed as not covered in the policy; specific modalities are described elsewhere in the document.
This placeholder preserves grouping for not‑covered procedures; refer to the exclusions and not medically necessary lists for explicit entries.
This placeholder maintains the inventory grouping for not covered items; the substantive exclusions are located in the policy text.
This placeholder maintains inventory consistency for items categorized as not covered; see the exclusions section for details.
This placeholder continues the not‑covered group structure; detailed not‑covered items are enumerated in the policy body.
Several neuromodulation techniques cited by VA/DoD and systematic reviews (for example, non‑invasive vagus nerve stimulation, external combined occipital and trigeminal systems, and certain tDCS/TMS applications) are noted to have insufficient evidence and are listed among modalities that may be considered not medically necessary outside research settings.
Clinical Context and Evidence Timeframe
Cervicogenic headache and occipital neuralgia are typically unilateral head pains attributed to pathology of the upper cervical spine or occipital nerves. Management ranges from conservative therapies (pharmacologic and noninvasive measures) to diagnostic/therapeutic occipital nerve injections, pulsed or thermal radiofrequency procedures, neurostimulation, and surgical approaches; however, evidence quality varies across modalities and many interventional or surgical approaches lack robust randomized controlled trial data.
The policy notes its evidence timeframe and related documentation updates in the revision history; recent changes include additions to definitions (MIDAS and MSQ) recorded in the Policy History for the 09/01/2025 version, and supporting evidence and references have been updated accordingly.
Operational Notes and Tools
Prior Authorization
Prior authorization and utilization review reminder
Verify the member's benefit plan and any utilization review tools (eg, InterQual) before service to confirm prior authorization requirements and coverage rules.
Plan terms govern coverage and may differ from this policy; cite plan citations in requests.
Use InterQual or other tools as directed by the payer if required.
Documentation Required
Plan verification required
Confirm and document the applicable federal, state, or contractual benefit plan terms (eg, New Jersey-specific requirements) because benefit plan provisions govern and may override policy statements.
Cite the member's specific plan terms and any state mandates in authorization documentation.
Note that plan requirements may require additional documentation beyond this policy.
Policy Update Log
2025-09-01material_changeLatest
Added definitions for the Migraine Disability Assessment Test (MIDAS) and the Migraine‑Specific Quality of Life Questionnaire (MSQ); Supporting Information, Clinical Evidence, and References updated; prior version CS086NJ.W archived.
Policy Summary
PayerUnitedHealthcare
PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for New Jersey Only)
Key ActionVerify member benefits and obtain prior authorization when required, documenting prior conservative therapy and diagnostic block or trial response.
Surgical technique uncertainty: There is insufficient evidence to establish superiority of one surgical approach (neurolysis vs neurectomy) or to conclude long-term benefit across techniques.insufficient high-quality data
Systematic reviews found only low-quality observational studies and no RCTs comparing techniques; selection and reporting biases limit inferences.
Potential risks including device complications, infection, need for revision/removal, and uncertainty of long-term benefit have been discussed with the patient and documented in the medical record.
Systematic reviews and ONS series report nontrivial complication and revision rates; documentation of informed consent and governance is recommended (NICE special arrangements where applicable).
Observational studies and reviews report better outcomes when prior diagnostic block response is present; documentation of prior trials and block response is emphasized for surgical selection.
inv-80: Require documented failure or intolerance of appropriate conservative therapies before invasive neuromodulation or PRF procedures
Require documented failure or intolerance of conservative therapies before invasive neuromodulation/PRF: Require documentation of failure or intolerance of appropriate conservative therapies (pharmacologic, behavioral, and less-invasive interventions) prior to considering invasive neuromodulation (ONS/SCS/PNS) or PRF procedures.
Technology assessments and cohort studies typically selected refractory patients who had exhausted conservative options prior to advanced interventions.
inv-81: Documented inadequate response to guideline-directed therapies or medication trials prior to neuromodulation
Document inadequate response to guideline-directed therapies before neuromodulation: Documented inadequate response to guideline‑directed pharmacologic and nonpharmacologic therapies or intolerance to these therapies is expected prior to authorizing neuromodulation procedures.
NICE and AHS guidance emphasize reserve for refractory cases and involvement of clinicians with migraine expertise.
inv-82: Document failure or intolerance of standard medical therapies prior to invasive neuromodulation per guideline recommendations
Document failure or intolerance per guideline recommendations: Document failure or intolerance of standard medical therapies prior to invasive neuromodulation in accordance with guideline recommendations; invasive treatments should be reserved for patients refractory to medical therapy.
NICE recommends invasive procedures only for distressing symptoms refractory to medical therapy and emphasizes documentation, governance, and specialist involvement.
Maintain informed consent and document discussion of risks, benefits, alternatives, and uncertainties for procedures identified by NICE as requiring special arrangements or research contexts.
Verify FDA 510(k) clearance status of devices used for RFA or electrical stimulation as part of device selection and procurement documentation (device clearance does not by itself determine coverage).
Billing Rule
Applicable Codes and Authorization Note
Applicable procedure and diagnosis codes are provided for provider reference only. Inclusion of a code in the list does not guarantee coverage or payment; check the member's benefit plan for coverage rules and prior authorization requirements.
Procedure and diagnosis codes may trigger prior authorization — submit full clinical documentation with authorization requests.
Use ICD-10 diagnosis codes that reflect the specific headache/occipital neuralgia diagnosis and any underlying etiologies (eg, cervicogenic headache, metastasis) per the member's medical record.
A ≥50% reduction in headache frequency and/or intensity is commonly used across trials to define a clinical responder.
Temporary ONS trial standardMost ONS studies selected individuals for permanent implantation based on a temporary trial typically showing ≥50% pain reduction lasting a few weeks.
Outcome measures tied to thresholdResponse definitions in reports include both ≥50% and ≥30% reductions; however, ≥50% is the most frequently used responder metric in guideline-oriented summaries.
Reported GONB practice pattern in seriesSeveral studies report repeated GONB performed weekly for up to 3–4 weeks followed by monthly maintenance injections in some series.
Example protocol (retrospective series)Hasırcı Bayır et al. described weekly GONB for three weeks then once monthly maintenance for up to six months based on clinical response.
RCT and prevention study schedulesOther trials (e.g., Özer et al.) repeated injections weekly for three weeks and followed participants for months to assess preventive effects.
RFA (occipital nerve) — no explicit frequency limits stated in these chunks
Frequency limits statedNo explicit numeric frequency limits for occipital nerve RFA are specified in the cited sections.
Durability and follow-up examplesMultiple studies report mean durations of pain relief (e.g., retrospective series with mean duration ~254 days), but protocols for repeat procedures are not standardized in these excerpts.
Need for further studyAuthors and reviews note that further study is necessary to establish RFA treatment protocols and repeat-session recommendations.
PRF / PRFN / RFA — no explicit frequency limits provided in this section
Frequency guidance present?The referenced PRF/PRFN sections do not provide explicit numeric frequency limits for repeat treatments.
Durability data examplesSome PRF series show effectiveness at 1–6 months with variable durability to 1–2 years (e.g., 77% at 1 month, 50% at 2 years in a supraorbital series), but do not define repeat timing.
Optimal targets/settings unclearReviews note heterogeneity in targets, settings, and image guidance; optimal PRF parameters and repeat schedules remain undefined.
Radiofrequency neurotomy (occipital) — repeat RFN not specified; evidence documents about six months of relief in several studies
Repeat RFN specificationRepeat radiofrequency neurotomy (RFN) is not specified in these excerpts; several studies documented about six months of pain relief after RFN.
Reported duration of reliefBest-practices and retrospective series note pain relief durations around six months in multiple studies, but longer-term repeat-session recommendations are not established.
Recommendation for further studyAuthors recommend further research before endorsing routine repeat RFN sessions in successfully treated individuals.
Local injection therapy — no frequency limits specified in this excerpt
Frequency limits specifiedNo explicit frequency limits for local injection therapy are provided in the cited excerpts.
FDA and off-label notesLocal anesthetics are FDA-approved for diagnostic/therapeutic nerve blockade; botulinum toxin A is FDA-approved for some indications but is off-label for cervicogenic headache and occipital neuralgia.
Practice variation documentedStudies and series report variable injection schedules (single diagnostic blocks, repeated GONB series, or maintenance protocols) without uniform frequency limits.
Include ultrasound use and anatomical targeting in documentation when applicable.
Billing Rule
Image guidance typically used and reported
Image guidance (ultrasound, CT, or fluoroscopy) is typically used and reported in studies for GONB, PRF, SPG PRFT, and C2 DRG procedures; procedural documentation should record the imaging modality.
Document whether US, CT, or fluoroscopy was used for targeting during the procedure.
Imaging modality selection and guidance technique should be available in the chart for authorization and billing review.
Billing Rule
PRF / nerve blocks — image guidance commonly used
Image guidance is commonly used for PRF and nerve block procedures; document guidance technique and targeting details in the procedure report.
CT- or US-guided PRF procedures are described in the literature.
Include needle placement, lesion settings (when applicable), and imaging confirmation in documentation.
Billing Rule
Occipital RFN — image evaluation when indicated
For occipital RFN and diagnostic evaluation, MRI and/or CT should be used when indicated to rule out other etiologies prior to neurotomy; include imaging reports in the prior authorization packet when obtained.
Imaging is not diagnostic for occipital neuralgia but is recommended to exclude alternative causes before RFN.
Attach MRI/CT reports to support the rationale for neurotomy when available.
Evaluation for cluster headache is case-dependent regarding imaging; follow guideline recommendations (eg, discuss neuroimaging for first bout with a clinician experienced in headache) and document the decision-making.
Document discussions with neurology or headache specialists about neuroimaging for cluster headache.
Record rationale for ordering or deferring imaging in the clinical record.
Evidence noteSurgical neurectomy lacks sufficient high-quality RCT evidence for routine recommendation in ON/headache indications per policy summaries.
Rhizotomy — surgical section of a nerve root to relieve pain (Taber's)
DefinitionRhizotomy: Surgical section of a nerve root to relieve pain (Taber's Medical Dictionary).
ApplicationIncluded among surgical interventions studied for occipital neuralgia and cervicogenic headache such as partial posterior rhizotomy and dorsal root section.
Evidence noteLong-term efficacy and RCT evidence for rhizotomy in ON/headache are insufficient per policy summaries.
GONB — greater occipital nerve block definition
DefinitionGreater occipital nerve block (GONB): Injection of a local anesthetic, often with or without corticosteroid, targeting the greater occipital nerve for diagnostic or therapeutic relief of occipital-related headaches.
Clinical roleUsed diagnostically to identify occipital nerves as pain generators and therapeutically for short-term pain relief in PDPH, migraine, and other headache disorders.
Imaging guidance and techniqueTrials report use of ultrasound guidance and variation in proximal vs distal targets; protocols vary across studies.
Neuroplasty — definition and limited literature context
DefinitionNeuroplasty: A minimally described interventional procedure intended to treat occipital neuralgia by neurolysis or decompression; literature is limited with no RCTs identified in reviewed summaries.
Evidence notePolicy notes inadequate published peer-reviewed literature to draw conclusions about safety and effectiveness for neuroplasty.
ImplicationAbsence of strong evidence may restrict routine coverage without further data or justification.
GONB (alternate chunk) — diagnostic/therapeutic local anesthetic injection description
DefinitionGONB (alternate description): A diagnostic and/or therapeutic local anesthetic (± steroid) injection targeting the greater occipital nerve to assess nerve-mediated headache and guide further interventions.
Use in trialsUsed in RCTs and observational series for PDPH, migraine, and cervicogenic headache with varying efficacy and short-term benefits reported.
Practice variationTechnique, target level (proximal vs distal), and image guidance (often ultrasound) vary across studies.
PRF / PRFT — definition of pulsed radiofrequency therapy
DefinitionPulsed radiofrequency (PRF / PRFT): A non-destructive RF modality delivering intermittent electric fields at lower temperatures intended to modulate nerve function without creating thermal lesions.
Clinical evidenceObservational and small prospective studies report short- to mid-term pain reduction (effects often present at 1–6 months; variable at 1–2 years), but optimal targets and settings remain unclear.
Safety/durability notePRF is often considered to have better safety than conventional thermal RFA, though evidence quality is low and further RCTs are needed.
DefinitionPulsed radiofrequency (PRF / PRFN): A non-ablative neuromodulation technique applying pulsed radiofrequency energy to peripheral nerves (e.g., GON, supraorbital nerve) intended to reduce pain without thermal lesioning.
Example durabilitySeries report effectiveness rates such as 77% at 1 month and 50% at 2 years in supraorbital neuralgia after single PRF, illustrating variable long-term durability.
Research needHeterogeneity in approaches and limited RCT data make definitive conclusions about efficacy and repeat treatment schedules uncertain.
Occipital nerve stimulation (ONS) — implanted PNS definition and trial process
DefinitionOccipital nerve stimulation (ONS): An implanted peripheral nerve stimulation targeting occipital nerves to reduce headache frequency/intensity, typically preceded by a temporary trial to assess response.
Trial processTemporary trials of ONS are commonly used to select candidates for permanent implantation; trials often required a positive response (commonly ≥50% reduction) lasting weeks.
Outcome variabilityReported long-term responder rates vary; selected cohorts report clinically meaningful long-term benefit in a subset of patients but with nontrivial complication and revision rates.
DefinitionRemote electrical neuromodulation (REN): A noninvasive, wearable device-based electrical neuromodulation therapy evaluated for migraine prevention in randomized trials.
RCT evidenceA multicenter RCT (Tepper et al.) enrolled 248 participants and demonstrated statistically significant reductions in migraine days and a higher proportion achieving 50% reduction in moderate/severe headache days with REN versus placebo.
Safety noteNo serious device-related adverse events were reported in the REN trial cited.
Temporary ONS trial — definition and typical positive-response threshold (≥50%)
DefinitionTemporary ONS trial: A short-term trial of occipital nerve stimulation typically used to assess candidacy for permanent implantation; commonly considered positive when yielding ≥50% reduction in pain for a period of weeks.
Study practiceHayes and multiple studies selected patients for permanent ONS implantation based on temporary trial responses of ≥50% that lasted for a few weeks.
Alternate thresholds usedSome series (e.g., Joswig et al.) used a ≥30% threshold to define trial responders in their cohort, illustrating variability in trial-response criteria across studies.
Diagnostic occipital nerve block — definition as diagnostic local anesthetic injection
DefinitionDiagnostic occipital nerve block: A local anesthetic injection to the occipital nerves used to help identify occipital nerves as the pain source prior to offering radiofrequency neurotomy or other targeted interventions.
Recommended sequencingBest-practices summary indicates diagnostic blockade should precede RFN, and a positive diagnostic block predicts better outcomes in several series.
Imaging and techniqueImage guidance (often ultrasound) is commonly used for GONB in clinical trials and practice to improve targeting.
Radiofrequency Ablation (RFA) — device/regulatory note and procedural definition
DefinitionRadiofrequency Ablation (RFA): A procedural intervention using RF devices (device components cleared via FDA 510(k)) to ablate neural tissue; devices (generators/probes) are regulated via FDA 510(k) product codes (e.g., GXD, GXI).
Regulatory noteThe procedure itself is not FDA-regulated but device components used to perform RFA are subject to 510(k) clearance per cited FDA product codes.
Policy revision notePolicy history (09/01/2025) updated clinical evidence and definitions including MIDAS/MSQ additions; RFA device regulation statements reference FDA listings accessed March 17, 2025.
DefinitionTranscutaneous/extracranial electrical stimulation: Noninvasive stimulation applied to branches of cranial nerves (e.g., supraorbital or occipital nerves) using FDA-cleared devices for acute or preventive migraine treatment.
Evidence qualityMeta-analyses and RCTs exist but overall evidence is limited and of low-to-moderate quality; NICE recommends research or special arrangements for some devices.
Device examplesNerivio and TENS/PENS modalities are discussed in the policy with varying levels of clearance and evidence across indications.
MIDAS — Migraine Disability Assessment Test (newly defined in policy)
DefinitionMIDAS (Migraine Disability Assessment Test): A validated questionnaire to assess migraine-related disability; a MIDAS score ≥6 indicates the need for discussion with a provider.
Scoring guidanceMIDAS totals are calculated from days reported in questions 1–5; score ranges link to disability categories (e.g., ≥21 = severe disability).
Policy updateThe MIDAS definition was added to the policy definitions in the 09/01/2025 revision.
MSQ — Migraine-Specific Quality of Life Questionnaire (newly defined in policy)
DefinitionMSQ (Migraine-Specific Quality of Life Questionnaire): A 14-item self-report instrument assessing role, emotional, and social functioning related to migraine.
Scoring/formatItems are rated on a 6-point Likert scale; the MSQ is widely used and validated across populations.
Policy updateMSQ definition was added to the policy definitions in the 09/01/2025 revision.
Temporary ONS trial (alternate reference) — included as supporting definition
Supporting reference (alternate chunk)Temporary ONS trial descriptions and responder thresholds (≥50%) are discussed in multiple sections and Hayes assessments, supporting the temporary-trial definition.
ContextHayes reports and other studies describe trial-to-implant pathways relying on temporary ONS trials with defined responder criteria.
Use in authorizationTemporary trial response documentation is commonly used in prior authorization decisions for permanent neurostimulator implantation.
This duplicate placeholder is retained for inventory completeness; refer to the primary not‑covered entries for clinical detail.